Collegium Appoints Vikram Karnani as Chief Executive Officer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/16/2026
- Wall St set for muted open as tech wobble persists; Tesla gains
- Oil heads for weekly gain with focus on Middle East supply
- Stay risk-off as higher real yields and AI volatility threaten stocks: BofA
- Appleās first foldable iPhone sells out within minutes as preorders begin
- CoreWeave bond rout tests market's math on AI buildout
- Vertiv shares fall on analyst downgrades and options bets
- European stocks rise, dollar set for weekly loss after yields drop
- S&P 500 ends higher as traders shift from AI to healthcare
- Rocket Lab USA (RKLB) Reiterated at Overweight by Cantor Fitzgerald as Neutron Launch Moved to Next Year
- Truist Financial to sell $7.7B LightStream loan portfolio to Carlyle
Collegium Pharmaceutical (COLL) PT Lowered to $40 at Jefferies
November 11, 2024 3:55 PM ESTJefferies analyst Glen Santangelo lowered the price target on Collegium Pharmaceutical (NASDAQ: COLL) to $40.00 (from $44.00) while maintaining a Buy rating.
The analyst comments "Model update post 3Q results. Overall, we remain encouraged by momentum in the underlying pain portfolio, coupled with new LT... More



